| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
81,510,000 |
| Market
Cap: |
1.77(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$17.69 - $45.07 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Beam Therapeutics is a biotechnology company. Co. has identified four development candidates to date: three from its ex vivo platform, with two candidates targeting hemoglobinopathies and one candidate targeting T-cell leukemia, and one from its in vivo platform targeting glycogen storage disease. BEAM-102 directly corrects the causative mutation in sickle cell disease by recreating a naturally-occurring normal human hemoglobin variant, HbG-Makassar. BEAM-201 is an anti-CD7, multiplex edited, allogeneic chimeric antigen receptor T cell development candidate for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
1,016,735 |
1,088,642 |
1,249,399 |
1,617,862 |
| Total Sell Value |
$31,322,673 |
$33,197,856 |
$38,301,409 |
$55,212,492 |
| Total People Sold |
6 |
6 |
6 |
6 |
| Total Sell Transactions |
9 |
12 |
17 |
40 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ciaramella Giuseppe |
President & CSO |
• – – |
2022-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
117,473 |
|
- |
|
| Evans John M. |
CEO |
• • – |
2022-01-31 |
4/A |
AS |
$63.45 |
$1,337,088 |
I/I |
(20,000) |
163,000 |
|
- |
|
| Evans John M. |
CEO |
• • – |
2022-01-31 |
4/A |
OE |
$1.03 |
$103,000 |
D/D |
100,000 |
1,038,825 |
|
- |
|
| Evans John M. |
CEO |
• • – |
2022-01-31 |
4/A |
AS |
$63.79 |
$2,004,815 |
D/D |
(30,000) |
938,825 |
|
- |
|
| Fmr Corp |
10% Owner |
– – • |
2022-01-20 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,989,617 |
|
-44% |
|
| Ciaramella Giuseppe |
President & CSO |
• – – |
2021-12-29 |
4 |
OE |
$0.67 |
$26,599 |
D/D |
39,700 |
102,473 |
|
- |
|
| Ciaramella Giuseppe |
President & CSO |
• – – |
2021-12-22 |
4 |
AS |
$85.39 |
$224,531 |
D/D |
(2,607) |
62,773 |
|
-53% |
|
| Ciaramella Giuseppe |
President & CSO |
• – – |
2021-12-22 |
4 |
OE |
$7.22 |
$18,823 |
D/D |
2,607 |
65,380 |
|
- |
|
| Ciaramella Giuseppe |
President & CSO |
• – – |
2021-12-21 |
4 |
AS |
$85.38 |
$2,151,249 |
D/D |
(25,104) |
62,773 |
|
-53% |
|
| Ciaramella Giuseppe |
President & CSO |
• – – |
2021-12-21 |
4 |
OE |
$7.22 |
$181,251 |
D/D |
25,104 |
87,877 |
|
- |
|
| Ciaramella Giuseppe |
President & CSO |
• – – |
2021-12-20 |
4 |
AS |
$85.20 |
$365,423 |
D/D |
(4,289) |
62,773 |
|
-53% |
|
| Ciaramella Giuseppe |
President & CSO |
• – – |
2021-12-20 |
4 |
OE |
$7.22 |
$30,967 |
D/D |
4,289 |
67,062 |
|
- |
|
| Evans John M. |
CEO |
• • – |
2021-11-16 |
4/A |
GD |
$0.00 |
$0 |
D/D |
12,000 |
968,825 |
|
- |
|
| Evans John M. |
CEO |
• • – |
2021-10-06 |
4 |
AS |
$82.71 |
$1,676,070 |
I/I |
(20,000) |
183,000 |
|
-12% |
|
| Evans John M. |
CEO |
• • – |
2021-10-06 |
4 |
AS |
$82.72 |
$2,321,198 |
D/D |
(27,700) |
1,033,525 |
|
-12% |
|
| Evans John M. |
CEO |
• • – |
2021-10-06 |
4 |
OE |
$1.03 |
$28,531 |
D/D |
27,700 |
1,061,225 |
|
- |
|
| Ciaramella Giuseppe |
President & CSO |
• – – |
2021-09-17 |
4 |
OE |
$0.67 |
$12,068 |
D/D |
18,012 |
62,773 |
|
- |
|
| Fmr Corp |
See Remark 1 |
– – – |
2021-08-25 |
4 |
A |
$0.00 |
$0 |
I/I |
793,736 |
1,744,221 |
|
- |
|
| Fmr Corp |
See Remark 1 |
– – – |
2021-08-25 |
4 |
D |
$0.00 |
$0 |
I/I |
(969,038) |
304 |
|
- |
|
| Fmr Corp |
See Remark 1 |
– – – |
2021-08-24 |
4 |
A |
$0.00 |
$0 |
I/I |
986,911 |
969,342 |
|
- |
|
| Fmr Corp |
See Remark 1 |
– – – |
2021-08-24 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,631,467) |
0 |
|
- |
|
| Evans John M. |
CEO |
• • – |
2021-08-19 |
4 |
OE |
$1.03 |
$12,360 |
D/D |
12,000 |
1,033,525 |
|
- |
|
| Evans John M. |
CEO |
• • – |
2021-08-19 |
4 |
AS |
$96.38 |
$1,989,744 |
I/I |
(20,000) |
203,000 |
|
-17% |
|
| Fmr Corp |
See Remark 1 |
– – • |
2021-08-09 |
4/A |
A |
$0.00 |
$0 |
I/I |
950,485 |
950,485 |
|
- |
|
| Fmr Corp |
See Remark 1 |
– – – |
2021-08-09 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,160,430) |
153 |
|
- |
|
169 Records found
|
|
Page 4 of 7 |
|
|
0.52 (2.45%) 
